Referral to alcohol treatment for patients with liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of systematically referring newly diagnosed patients with alcohol-related liver disease (ALD) to specialized alcohol use disorder (AUD) treatment. It is a randomized controlled trial comparing the outcomes of patients receiving standard care versus those receiving standard care plus a referral to AUD treatment. The primary goal is to assess the rate of alcohol abstinence after six months. Participants will be randomized during their first visit, and the study will utilize an existing observational cohort for control comparisons.

Why it matters

Who can join: the full rules

Inclusion criteria

* Age \> 18 years
* Newly diagnosed alcohol-related liver disease, defined as within six months from baseline visit.
* A liver stiffness above 8.0 kPa with 10 successful measurements and an interquartile range of less than 30% as assessed with transient elastography.
* Excessive alcohol consumption defined as \>7 units/week for women and \>14 units/week for men within the previous year.
* The patient is able to understand the purpose of the study and give informed oral and written consent to participate.

Exclusion criteria

* Not enough proficiency in Danish to participate in interviews and questionnaires.
* Pregnancy
* Ongoing specialized AUD treatment. Self-help groups and AUD counselling at general practitioners are not counting as specialized AUD treatment in this study.

Where it's running

• Department of Medicine, Zealand University Hospital
  Køge, Køge, Denmark Recruiting

Study contacts

• Study coordinator: Emil B B Fromberg, Cand.scient.san
• Email: ebuf@regionsjaelland.dk
• Phone: 51184036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• Tirzepatide's effects on alcohol intake in patients with schizophrenia and alcohol use disorder

  This study is testing if the medication tirzepatide can help people with schizophrenia and alcohol use disorder drink less alcohol over six months.

  Recruiting at 2 sites Phase 2 Psychiatric Centre Rigshospitalet · Aalborg, Denmark and 1 other locations · NCT06939088

• Functional connectivity–guided transcranial magnetic stimulation for alcohol use disorder

  This study will test whether a single fMRI-guided session of transcranial magnetic stimulation (TMS) can reduce alcohol-cue brain reactivity and help people with moderate-to-severe alcohol use disorder stay abstinent.

  Recruiting VA Palo Alto Health Care System · Palo Alto, California · NCT06415721

• Using psilocybin with therapy to help reduce heavy drinking in people with alcohol use disorder

  This study is testing if a single dose of psilocybin, along with therapy, can help people with alcohol use disorder drink less over 12 weeks.

  Recruiting Phase 2 University of Calgary · Calgary, Alberta · NCT05995769

• Evaluating liver disease screening for individuals with alcohol use disorder

  This study tests if screening for liver disease with a special measurement helps people in alcohol treatment stay sober or drink less over six months.

  Recruiting at 2 sites Zealand University Hospital · Køge and 1 other locations · NCT05855031

• Naltrexone treatment for heavy drinkers with Alcohol Use Disorder

  This study is testing if a long-acting injection of naltrexone can help heavy drinkers cut back on their alcohol use.

  Recruiting Phase 4 University of Pennsylvania · Philadelphia, Pennsylvania · NCT05028062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.